Reports Q3 revenue $4.71M, consensus $4.14M. “2025 continues to be a highly productive year with significant accomplishments in both partnered and wholly owned programs,” said Dinesh V. Patel, the Company’s President and CEO. “In addition to the NDA and EMA submissions for icotrokinra for psoriasis, we are pleased to see our partner Johnson and Johnson expand the ICONIC program into additional IL-23 pathway relevant and validated I&I indications, namely psoriatic arthritis, ulcerative colitis, and Crohn’s disease. We, along with our partner Takeda, eagerly await the presentation of the rusfertide 52-week VERIFY data at ASH in December and the NDA filing for rusfertide by year end.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- PTGX Earnings this Week: How Will it Perform?
- Protagonist Therapeutics price target raised to $88 from $76 at Truist
- Protagonist Therapeutics: Promising Prospects and Increased Price Target Amidst Positive Study Data and Strategic Partnerships
- Protagonist Therapeutics: Promising Drug Development and Strong Clinical Progress Justify Buy Rating
- Promising Potential of Protagonist Therapeutics’ Icotrokinra Drives Buy Rating Amid Strategic Interest from Johnson & Johnson